Multiple Sclerosis International Federation guideline methodology for off-label treatments for multiple sclerosis.

ABSTRACT:

Background

A total of 2.8 million people are living with multiple sclerosis and due to disparities in access to medicines, the ability to treat this condition varies widely. Off-label disease-modifying therapies are sometimes more available or affordable in different health systems. Appropriate methodology is integral in creating high-quality and trustworthy guidelines. In this article, we outline Multiple Sclerosis International Federation's (MSIF) approach to creating guidelines for off-label treatments for multiple sclerosis.

Methods

We use the Guidelines International Network (GIN)-McMaster Guideline Development Checklist and the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) Evidence-to-Decision (EtD) framework. We developed detailed health

SUBMITTER: Piggott T 

PROVIDER: S-EPMC8655455 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature